Vaxcyte (NASDAQ:PCVX) EVP Sells $127,507.50 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $56.67, for a total value of $127,507.50. Following the completion of the sale, the executive vice president owned 145,435 shares of the company’s stock, valued at approximately $8,241,801.45. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total value of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total transaction of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00.

Vaxcyte Price Performance

Shares of PCVX opened at $56.48 on Monday. The company has a market capitalization of $8.40 billion, a PE ratio of -7.40 and a beta of 1.23. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $65.00. The company’s fifty day moving average price is $58.67 and its 200 day moving average price is $56.18.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the firm earned ($1.22) EPS. Analysts anticipate that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Hedge Funds Weigh In On Vaxcyte

Several large investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its position in shares of Vaxcyte by 143.4% in the 2nd quarter. First Light Asset Management LLC now owns 345,157 shares of the company’s stock worth $20,064,000 after acquiring an additional 203,373 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Vaxcyte in the second quarter valued at $1,906,000. IFP Advisors Inc raised its stake in shares of Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after purchasing an additional 236 shares in the last quarter. Arizona State Retirement System lifted its position in Vaxcyte by 4.3% in the second quarter. Arizona State Retirement System now owns 33,755 shares of the company’s stock worth $1,962,000 after purchasing an additional 1,394 shares during the period. Finally, Nykredit A S bought a new position in Vaxcyte in the second quarter worth $280,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on PCVX shares. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Needham & Company LLC restated a “buy” rating and issued a $110.00 price objective on shares of Vaxcyte in a research note on Friday, September 25th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Bank of America reduced their price target on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a report on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.40.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.